US Patent

US12527810 — Pharmaceutical composition, methods for treating and uses thereof

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2033-04-22 · 7y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using a SGLT-2 inhibitor to treat or prevent conditions such as type 1 diabetes mellitus and hyperglycemia.

USPTO Abstract

The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Drugs covered by this patent

Jardiance (empagliflozin) · Boehringer Ingelheim

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4403`	—	Jardiance
`U-4403`	—	Jardiance
`U-4403`	—	Jardiance
`U-4403`	—	Jardiance
`U-4403`	—	Jardiance
`U-4403`	—	Jardiance

Patent Metadata

Patent number: US12527810
Jurisdiction: US
Classification: Method of Use
Expires: 2033-04-22
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.